Advertisement

Derzeitiges Verständnis immunologisch-onkologischer Prinzipien

  • V. Schirrmacher
Conference paper

Zusammenfassung

Immune Effektorzellen mit potentiell antitumoraler bzw. antimetastatischer Aktivität können unterschiedliche Phänotypen und Funktionen haben. In Tabelle 1 sind derartige Zelltypen zusammengestellt und die Spezifität der jeweiligen Zielzellerkennung sowie die funktionalen Aktivitäten aufgelistet. Bei der Tumorzellerkennung durch T-Lymphozyten spielen die Moleküle des Haupthistokompatibilitätskomplexes (MHC) eine entscheidende Rolle. So erkennen zytotoxische T-Lymphozyten (CTL) ihre Zielstrukturen als endogene intrazelluläre Peptide, die vermittels MHC-Klasse-I-Molekülen an die Zelloberfläche gebracht werden (Abb. 1). T-Helferzellen, die durch das CD4-Molekül charakterisiert sind, erkennen dagegen exogene prozessierte Proteinfragmente, wenn diese mit MHC-Molekülen der Klasse II auf der Zelloberfläche antigenpräsentierender Zellen (APC) dargeboten werden. Nach Kontakt mit dem spezifischen Zielzellantigen können T-Effektorlym-phozyten unter geeigneten Umständen zu zytotoxischen T-Zellen ausreifen, die die Zielzellen direkt lysieren. T-Helferlymphozyten sekretieren nach spezifischer Stimulation durch APC unterschiedliche Lymphokine, die zur Rekrutierung und Aktivierung anderer Zellen, wie z.B. Makrophagen oder B-Lymphozyten führen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Barnd DI, Lan MS, Metzgar RS, Finn OJ (1989) Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic Tcells. Proc Natl Sci USA 86: 7159–7163CrossRefGoogle Scholar
  2. Bonomi PD, Finkelstein DM, Ruckdeschel JC et al. (1989) Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: A study of the Eastern Cooperative Oncology Group. J Clin Oncol 7: 1602–1613PubMedGoogle Scholar
  3. Fearon E, Pardoll D, ItayaTet al. (1990) Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60: 397–403PubMedCrossRefGoogle Scholar
  4. Gansbacher B, Zier K, Daniels B, Cronin K, Bannedi R, Gilboa E (1990a) Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 172: 1217–1224PubMedCrossRefGoogle Scholar
  5. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E (1990b) Retroviral vector-mediated gamma interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 50: 7820–7825PubMedGoogle Scholar
  6. Kast WM, Offringa R, Peters PJ, Voordouw AC, Meloen RH, Van der Eb AJ, Melief CJ (1989) Eradication of adenovirus El-induced tumors by E1A-specific cytotoxic T lymphocytes. Cell 59: 603–614PubMedCrossRefGoogle Scholar
  7. Kaya FJ, Bunn PA Jr, Steinberg SM et al. (1989) A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New Engl J Med 321: 1784–1790CrossRefGoogle Scholar
  8. Lassam N, Jay G (1989) Suppression of MRC class I RNA in highly oncogenic cells occurs at the level of transcription initiation. J Immunol 143: 3792–3797PubMedGoogle Scholar
  9. Lurquin C, Van Pel AI, Mariame B et al. (1989) Structure of the gene of turn- transplantation antigen P 91 A: the mutated exon encodes a peptide recognized with Ld by cytolytic Tcells. Cell 58: 293–303PubMedCrossRefGoogle Scholar
  10. Maki RG, Old LJ, Strivastava PK (1990) Human homologue of murine tumor rejection antigen gp 96: 5′ regulatory and coding regions and relationship to stress-induced proteins. Proc Natl Acad Sci 87: 5658–5662PubMedCrossRefGoogle Scholar
  11. Mukerji B, Chakraborty NG, Sivanandham M (1990) T-cell clones that react against autologous human tumors. Immunol Rev 116: 33–62CrossRefGoogle Scholar
  12. Notter M, Schirrmacher V (1990) Tumor-specific T-cell clones recognize different protein determinants of autologous human malignant melanoma cells. Int J Cancer 45: 834–841PubMedCrossRefGoogle Scholar
  13. Osband ME, Ross S (1990) Problems in the investigational study and clinical use of cancer immunotherapy. Imm Today 11: 193–195CrossRefGoogle Scholar
  14. Perdrizet GA, Ross SR, Stauss HJ, Singh S, Koeppen H, Schreiber H (1990) Animals bearing malignant grafts reject normal grafts that express through gene transfer the same antigen. J Exp Med 171: 1205–1220PubMedCrossRefGoogle Scholar
  15. Porgador A, Feldman M, Eisenbach L (1989) H-2Kb transfection of B16 melanoma cells results in reduced tumorigenicity and metastatic competence. J Immunogenet 16: 291–303PubMedCrossRefGoogle Scholar
  16. Schwartz RH (1990) A cell culture model for T lymphocyte clonal anergy. Science 248: 1349–1359PubMedCrossRefGoogle Scholar
  17. Sibille C, Chomez P, Wildmann C et al. (1990) Structure of the gene of turn- transplantation antigen P198: a point-mutation generates a new antigenic peptide. J Exp Med 172:35–45PubMedCrossRefGoogle Scholar
  18. Szikora J, Van Pel A, Brichard V et al. (1990) Structure of the gene of turn-transplantation antigen P35B: presence of a point mutation in the antigenic allele. EMBO J 9: 104Google Scholar
  19. Tepper R, Pattengale P, Leder P (1989) Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57: 503–512PubMedCrossRefGoogle Scholar
  20. Van der Bruggen P, Traversari C, Chomez P et al. (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643PubMedCrossRefGoogle Scholar
  21. Versteeg R, Kruse-Wolters KM, Plomp AC et al. (1989a) Suppression of class I human HLA by c-myc is locus specific. J Exp Med 170: 621–635PubMedCrossRefGoogle Scholar
  22. Versteeg R, Peltenberg L, Plomp AC, Schreier PI (1989b) High expression of the c-myc oncogene renders melanoma cells prone to lysis by NK cells. J Immunol 143: 4331–4337PubMedGoogle Scholar
  23. Ward P, Koeppen H, Hurteau T, Rowley D, Schreiber H (1990) Major histocompatibility complex class I and unique antigen expression by murine tumors that escaped from CD8+ T-cell-dependent surveillance. Cancer Res 50: 3851–3858PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • V. Schirrmacher

There are no affiliations available

Personalised recommendations